PolarityTE Names Board Member David Seaburg as President of
Jan 31, 2019 12:45:32 GMT
icemandios likes this
Post by c2crusher on Jan 31, 2019 12:45:32 GMT
PolarityTE Names Board Member David Seaburg as President of Corporate Development
ir.polarityte.com/PolarityTE-Names-Board-Member-David-Seaburg-as-President-of-Corporate-Development
SALT LAKE CITY, Jan. 29, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) announced today that David Seaburg will join the Company in the newly-created role of President of Corporate Development. PolarityTE is a commercial-stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences.
PolarityTE (PRNewsfoto/PolarityTE, Inc.)
In his new role, Mr. Seaburg will shape PolarityTE's corporate development strategy, including industry and institutional investor relationships, accretive acquisitions, strategic communications and programs that support the Company's enterprise and growth plans. Mr. Seaburg will retain his seat on the Company's Board of Directors, which he has held since August 2018.
Dr. Denver M. Lough, Chairman and Chief Executive Officer of PolarityTE, said, "David has been an incredible contributor on our Board of Directors since he joined last year. His guidance as a director, deep knowledge of healthcare issues and expertise in financial and business transactions, make David the perfect choice to lead our corporate development efforts. We are thrilled to welcome David as a full-time member of the company, and look forward to benefitting from his ongoing leadership, expertise and guidance as we pursue the development of PolarityTE."
Mr. Seaburg spent the past 25 years of his career at Cowen, a leading healthcare franchise in equities research, sales and trading and investment banking. For the past 15 years, he served as Cowen's Managing Director and Head of Sales Trading, where he cultivated and led teams operating across multiple disciplines and specialties, where he leveraged human capital to drive the organization's success. Over the course of his tenure, he interacted with thousands of healthcare investors and corporate management teams. Mr. Seaburg was also a CNBC Fast Money Contributor, where he provided regular on-air market commentary for the network.
"Since joining the Board of Directors, I have learned a great deal about the company's proprietary technology and its potential impact on the healthcare industry. Tissue regeneration has been a concept discussed for decades by myself and others within healthcare equities and banking circles. I believe PolarityTE has a game-changing technology that brings that discussion to the forefront of patient care by challenging what constitutes effective therapies and clinical standards of care, and which creates exciting corporate development opportunities," said Mr. Seaburg.
Crusher
ir.polarityte.com/PolarityTE-Names-Board-Member-David-Seaburg-as-President-of-Corporate-Development
SALT LAKE CITY, Jan. 29, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) announced today that David Seaburg will join the Company in the newly-created role of President of Corporate Development. PolarityTE is a commercial-stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences.
PolarityTE (PRNewsfoto/PolarityTE, Inc.)
In his new role, Mr. Seaburg will shape PolarityTE's corporate development strategy, including industry and institutional investor relationships, accretive acquisitions, strategic communications and programs that support the Company's enterprise and growth plans. Mr. Seaburg will retain his seat on the Company's Board of Directors, which he has held since August 2018.
Dr. Denver M. Lough, Chairman and Chief Executive Officer of PolarityTE, said, "David has been an incredible contributor on our Board of Directors since he joined last year. His guidance as a director, deep knowledge of healthcare issues and expertise in financial and business transactions, make David the perfect choice to lead our corporate development efforts. We are thrilled to welcome David as a full-time member of the company, and look forward to benefitting from his ongoing leadership, expertise and guidance as we pursue the development of PolarityTE."
Mr. Seaburg spent the past 25 years of his career at Cowen, a leading healthcare franchise in equities research, sales and trading and investment banking. For the past 15 years, he served as Cowen's Managing Director and Head of Sales Trading, where he cultivated and led teams operating across multiple disciplines and specialties, where he leveraged human capital to drive the organization's success. Over the course of his tenure, he interacted with thousands of healthcare investors and corporate management teams. Mr. Seaburg was also a CNBC Fast Money Contributor, where he provided regular on-air market commentary for the network.
"Since joining the Board of Directors, I have learned a great deal about the company's proprietary technology and its potential impact on the healthcare industry. Tissue regeneration has been a concept discussed for decades by myself and others within healthcare equities and banking circles. I believe PolarityTE has a game-changing technology that brings that discussion to the forefront of patient care by challenging what constitutes effective therapies and clinical standards of care, and which creates exciting corporate development opportunities," said Mr. Seaburg.
Crusher